BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 14, 2019
View Archived Issues
TFEB initiates fat cell browning
Read More
Diabetes drug eases nicotine withdrawal
Read More
SHR-4640: a potential new hyperuricemia treatment option
Read More
First-in-class fusion inhibitor against diverse and multidrug-resistant HCV strains presented
Read More
Mouse-human chimeric anti-CXADR antibody shows antitumor activity in prostate and SCLC models
Read More
Results from multiple phase III studies of anemia treatment roxadustat presented
Read More
First patient dosed in phase I/II study of the bicycle toxin conjugate BT-5528
Read More
First-in-human data for ASN-007 presented
Read More
Urinary TIMP2 and IGFBP7 as early biomarkers to predict drug induced AKI
Read More
MG-1131, a novel anti-TIGIT monoclonal antibody with promising in vitro efficacy
Read More
Phase I data reported for FPT-155 in patients with advanced solid tumors
Read More
Anti-LAG-3 monoclonal antibodies described by Pharmaexplorer, Shanghai Pharmaexplorer
Read More
KINE-101, a novel synthetic peptide for rheumatoid arthritis
Read More
AlaMab Therapeutics discloses connexin-43 antibodies
Read More
Sumitomo Dainippon Pharma patents mGlu2 receptor negative allosteric modulators
Read More
Shanghai Leadopharma Technology presents antiepileptic compounds
Read More
Sichuan Kelun-Biotech Biopharmaceutical identifies new arginase-1 inhibitors
Read More
Phase I/II study of DF-1001 in advanced HER2-expressing sold tumors begins dosing
Read More
Bacteriophage "cocktail" fights drinking sequelae, PSC
Read More
Phase IIa study of THX-110 in obstructive sleep apnea meets primary endpoint
Read More
Pivotal study of Nucala in hypereosinophilic syndrome meets primary endpoint
Read More
SQZ-PBMC-HPV begins phase I study in HPV+ recurrent, locally advanced or metastatic solid tumors
Read More
Daiichi Sankyo opens enrollment for phase II study of valemetostat in relapsed/refractory ATL
Read More
Kiadis terminates development of ATIR-101, refocuses on NK-cell therapy platform
Read More
New phase II trial evaluates KN-019 in rheumatoid arthritis
Read More